Effects of Multimodal Analgesia on Serum MCP-1, BDNF, and MiRNA-124 in Hysterectomy Surgery
CompletedNot applicableNCT05069311
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The inflammatory process is the main mechanism in the occurrence of acute postoperative pain. It is also the main risk for the development of acute pain into persistent pain. Inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. Postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.
Study details
- Official title
- Effects of Multimodal Analgesia on Monocyte Chemoattractant Protein-1, Brain-derived Neurotrophic Factor, and RNA-124 Micro to Acute Pain in Patients Who Underwent Hysterectomy
- Conditions
- Inflammation
- Inflammatory Response
- Acute Pain
- Chronic Pain
- Interventions
- Drug: Multimodal analgesia
- Drug: Conventional intravenous analgesia
- Sponsor
- Udayana University
- Start date
- 2021-10-15
- Primary completion
- 2022-03-30
- Sex
- Female
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Indonesia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Scheduled for elective hysterectomy * American Society of Anesthesiologists (ASA) physical status 1 to 3 Exclusion Criteria: * allergy to studied drugs * history of chronic pain * history of hepatitis, depression, peptic ulcer, or acute myocardial infarction * receive intraoperative massive blood transfusion * prolonged coagulation * body mass index \>35 kg/m2 * patients with neurological deficits * taking anti-platelet medications
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05069311